Treatment News : Dramatic Drop in Antibiotic-Resistant Gonorrhea

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 19, 2014

Dramatic Drop in Antibiotic-Resistant Gonorrhea

Rates of drug-resistant gonorrhea, once on the rise, have fallen significantly in the United States over the past few years, aidsmap reports. The Centers for Disease Control and Prevention (CDC), which attributes the turn-around to two revisions the agency made to gonorrhea treatment guidelines in 2010 and 2012, presented these findings at the U.S. 2014 STD Prevention Conference in Atlanta.

Between 2006 and 2010, the rate at which gonorrhea cases were resistant to the antibiotic cefixime increased from less than 0.1 percent to 1.4 percent. The recommended treatment during that period was either an oral dose of cefixime or an intramuscular dose of ceftriaxone. In December 2010, to combat drug resistance, the CDC changed its recommended treatment protocol to a double dose of intramuscular ceftriaxone or, alternatively, cefixime plus either azithromycin or doxycycline. Because drug resistance rates did not subsequently ebb, the CDC then made another shift in August 2012, recommending double-dose injected ceftriaxone with azithromycin or doxycycline.

This shift, along with better adherence among STI clinics to gonorrhea treatment regimens, seems to have succeeded in fighting back a the drug-resistant tide.

Between 2011 and 2012, the rate of cefixime-resistant gonorrhea dropped from 1.4 percent to 0.9 percent, and then to 0.4 percent in 2013. The rates dropped the most dramatically among gay men: from 4 percent in 2010 to 0.6 percent in 2013. In 2011 ceftriaxone resistance stood at 0.38 percent among all Americans and 0.95 percent among gays; these figures then dropped to a respective 0.03 percent and 0.07 percent by 2013.

The CDC cautions that, while these figures may be cause for celebration, gonorrhea has still developed resistance to all arsenals used to combat the infection through history. “The potential that gonorrhea could become untreatable remains real,” the agency states as it promotes both the development of new treatments as well as improved prevention.

To read the aidsmap story, click here.

Search: Drug-resistance, antibiotics, gonorrhea, aidsmap, Centers for Disease Control and Prevention, CDC, 2014 STD Prevention Conference, cefixime, ceftriaxone, azithromycin, doxycyline.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.